Survey Reveals Blind Spots with GenAI Implementation in Healthcare

A recent survey by N.Y.-based Deloitte, which surveyed 60 healthcare executives, exposes blind spots that may prevent healthcare systems from successfully incorporating GenAI into their workflows. Deloitte’s 2024 Health Care Generative AI Outlook underscores that health care leaders may not consider what consumers like to see, which is transparency in AI use, according to Deloitte’s 2023 Health Care Consumer Survey. Many healthcare organizations are expected to ramp up their AI investments this year, anticipating increasing efficiency and effectiveness.

Findings from the report suggest that 70 percent of executives are primarily focused on data availability, quality, compliance, security, and privacy. Blind spots were defined as topics that less than 60 percent of executives are concentrated on. The identified pitfalls per the report are that effective governance gets lost due to other data priorities, healthcare leaders aren’t considerate enough to consumer’s concerns, and investing in the workforce is not a high priority.

Deloitte writers advise that “Organizations could increasingly benefit from a robust overarching framework that focuses equally on consumers, governance, and the workforce.” Key considerations include establishing effective governance through creating centers of excellence, building consumer trust by engaging with consumers to gain understanding, gaining staff buy-in, and constructing solutions for scalability.

Per the report, “By addressing consumer and workforce considerations alongside the data considerations, health care organizations can pave the way for a future in which generative AI not only augments health care delivery but does so equitably, without bias, in a trustworthy and ethical way, along with a personal touch.”